JP2016509582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016509582A5 JP2016509582A5 JP2015549737A JP2015549737A JP2016509582A5 JP 2016509582 A5 JP2016509582 A5 JP 2016509582A5 JP 2015549737 A JP2015549737 A JP 2015549737A JP 2015549737 A JP2015549737 A JP 2015549737A JP 2016509582 A5 JP2016509582 A5 JP 2016509582A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- human
- molecule
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 90
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 64
- 206010028980 Neoplasm Diseases 0.000 claims description 54
- 210000004027 cell Anatomy 0.000 claims description 44
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims description 32
- 102000055298 human VTCN1 Human genes 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 31
- 201000011510 cancer Diseases 0.000 claims description 28
- 210000004981 tumor-associated macrophage Anatomy 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 208000035473 Communicable disease Diseases 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 230000001404 mediated effect Effects 0.000 claims description 16
- 210000004881 tumor cell Anatomy 0.000 claims description 16
- 230000001629 suppression Effects 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 239000002246 antineoplastic agent Substances 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 238000003556 assay Methods 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 230000002380 cytological effect Effects 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 230000001747 exhibiting effect Effects 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 5
- 230000002147 killing effect Effects 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 206010062016 Immunosuppression Diseases 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 4
- 238000001815 biotherapy Methods 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 238000001794 hormone therapy Methods 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 230000001506 immunosuppresive effect Effects 0.000 claims description 4
- 238000009169 immunotherapy Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 230000005909 tumor killing Effects 0.000 claims description 4
- 230000034994 death Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 claims description 2
- 238000003364 immunohistochemistry Methods 0.000 claims description 2
- 210000004882 non-tumor cell Anatomy 0.000 claims description 2
- 230000006037 cell lysis Effects 0.000 claims 2
- 238000011394 anticancer treatment Methods 0.000 claims 1
- 206010057248 Cell death Diseases 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261739287P | 2012-12-19 | 2012-12-19 | |
| US201261739272P | 2012-12-19 | 2012-12-19 | |
| US201261739353P | 2012-12-19 | 2012-12-19 | |
| US61/739,353 | 2012-12-19 | ||
| US61/739,287 | 2012-12-19 | ||
| US61/739,272 | 2012-12-19 | ||
| PCT/US2013/076701 WO2014100483A1 (en) | 2012-12-19 | 2013-12-19 | Anti-human b7-h4 antibodies and their uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016509582A JP2016509582A (ja) | 2016-03-31 |
| JP2016509582A5 true JP2016509582A5 (enExample) | 2017-01-19 |
Family
ID=49917300
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549737A Pending JP2016509582A (ja) | 2012-12-19 | 2013-12-19 | 抗ヒトｂ７−ｈ４抗体およびその使用 |
| JP2015549721A Pending JP2016505843A (ja) | 2012-12-19 | 2013-12-19 | Ｂ７−ｈ４特異的抗体、並びにその組成物及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549721A Pending JP2016505843A (ja) | 2012-12-19 | 2013-12-19 | Ｂ７−ｈ４特異的抗体、並びにその組成物及び使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9574000B2 (enExample) |
| EP (2) | EP2934575A2 (enExample) |
| JP (2) | JP2016509582A (enExample) |
| KR (1) | KR20150100716A (enExample) |
| CN (1) | CN104955475A (enExample) |
| AU (2) | AU2013361231A1 (enExample) |
| BR (1) | BR112015014063A2 (enExample) |
| CA (2) | CA2894689A1 (enExample) |
| HK (1) | HK1210027A1 (enExample) |
| MX (1) | MX2015007846A (enExample) |
| RU (1) | RU2015129551A (enExample) |
| SG (1) | SG11201504764SA (enExample) |
| WO (2) | WO2014100439A2 (enExample) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012145568A1 (en) * | 2011-04-21 | 2012-10-26 | Albert Einstein College Of Medicine Of Yeshiva University | Antibodies to human b7x for treatment of metastatic cancer |
| US9676854B2 (en) * | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
| EP2773651B1 (en) | 2011-11-03 | 2020-12-23 | The Trustees of the University of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
| EA201591750A1 (ru) | 2013-03-14 | 2016-05-31 | Дженентек, Инк. | Антитела против b7-h4 и иммуноконъюгаты |
| ITMI20130692A1 (it) | 2013-04-26 | 2014-10-27 | Copan Italia Spa | Dispositivo e procedimento per il processamento automatico di piastre di coltura per campioni microbiologici |
| SG11201605046YA (en) | 2013-12-20 | 2016-07-28 | Hutchinson Fred Cancer Res | Tagged chimeric effector molecules and receptors thereof |
| US10059768B2 (en) * | 2014-09-12 | 2018-08-28 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| IL283834B (en) * | 2014-09-28 | 2022-07-01 | Univ California | Modulation of stimulatory and non-stimulatory myeloid cells |
| US10626176B2 (en) * | 2014-10-31 | 2020-04-21 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind B7-H4 |
| AU2016233495B2 (en) | 2015-03-13 | 2022-02-24 | Cytomx Therapeutics, Inc | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof |
| EP3274369A4 (en) * | 2015-03-27 | 2018-10-17 | University of Southern California | Car t-cells for the treatment of b7-h4 expressing solid tumors |
| WO2016176652A2 (en) | 2015-04-29 | 2016-11-03 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
| SG10202110908WA (en) | 2015-05-04 | 2021-11-29 | Cytomx Therapeutics Inc | Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof |
| SMT202200118T1 (it) | 2015-11-03 | 2022-05-12 | Janssen Biotech Inc | Anticorpi che legano specificamente pd-1 e loro usi |
| SG10201601719RA (en) | 2016-03-04 | 2017-10-30 | Agency Science Tech & Res | Anti-LAG-3 Antibodies |
| SG10201603721TA (en) | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
| CN109563503B (zh) | 2016-07-26 | 2023-09-29 | 静冈县 | 抗b7-h4抗体 |
| EP3516044B1 (en) | 2016-09-23 | 2025-04-16 | Fred Hutchinson Cancer Center | Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof |
| JP7037577B2 (ja) | 2017-03-15 | 2022-03-16 | フレッド ハッチンソン キャンサー リサーチ センター | 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用 |
| EP3612567B1 (en) * | 2017-04-19 | 2024-09-11 | Bluefin Biomedicine, Inc. | Anti-vtcn1 antibodies and antibody drug conjugates |
| CN110891567B (zh) | 2017-05-24 | 2024-01-09 | 效应治疗股份有限公司 | 用于改善的抗肿瘤免疫应答的组合物和方法 |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| US10814011B1 (en) | 2017-06-16 | 2020-10-27 | Nantbio, Inc. | Anti-B7-H4 antibodies and methods |
| EA202090247A1 (ru) * | 2017-07-14 | 2020-05-12 | Цитомкс Терапьютикс, Инк. | Антитела против cd166 и их применения |
| AU2018301716B2 (en) | 2017-07-14 | 2024-06-13 | The Regents Of The University Of California | Novel methods of predicting transplant rejection risk |
| JP2020533962A (ja) | 2017-08-11 | 2020-11-26 | フレッド ハッチンソン キャンサー リサーチ センター | Ｂｒａｆ特異的ｔｃｒおよびその使用 |
| BR112020003533A2 (pt) * | 2017-08-25 | 2020-11-17 | Five Prime Therapeutics, Inc. | anticorpos b7-h4 e métodos de uso dos mesmos |
| CN111065409A (zh) | 2017-09-06 | 2020-04-24 | 弗雷德哈钦森癌症研究中心 | Strep-tag特异性结合蛋白及其用途 |
| CA3071661A1 (en) | 2017-09-06 | 2019-03-14 | Fred Hutchinson Cancer Research Center | Strep-tag specific chimeric receptors and uses thereof |
| EP3678690A1 (en) | 2017-09-06 | 2020-07-15 | Fred Hutchinson Cancer Research Center | Methods for improving adoptive cell therapy |
| US20210069241A1 (en) | 2017-10-20 | 2021-03-11 | Fred Hutchinson Cancer Research Center | Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression |
| WO2019109047A1 (en) | 2017-12-01 | 2019-06-06 | Fred Hutchinson Cancer Research Center | Binding proteins specific for 5t4 and uses thereof |
| WO2019140278A1 (en) | 2018-01-11 | 2019-07-18 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting core binding factor antigens |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| BR112020014929A2 (pt) * | 2018-01-23 | 2020-12-08 | Nextcure, Inc. | Composição farmacêutica, métodos para aumentar, para reduzir, para intensificar ou induzir uma resposta imune em um indivíduo, molécula, anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo, ácido nucleico, anticorpo monoclonal anti-b7h4 ou fragmento de ligação ao antígeno do mesmo, anticorpo anti-b7h4 ou fragmento de ligação ao antígeno do mesmo, cadeias leve e pesada de anticorpo anti-b7h4, e, cadeias leve e pesada de anticorpo |
| EP3753951A4 (en) * | 2018-02-11 | 2022-03-16 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | ANTI-B7-H4 ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF |
| EP3752525A1 (en) | 2018-02-12 | 2020-12-23 | Fred Hutchinson Cancer Research Center | Cyclin a1 specific t cell receptors and uses thereof |
| CN111741978A (zh) | 2018-02-21 | 2020-10-02 | 戊瑞治疗有限公司 | B7-h4抗体制剂 |
| MX2020008730A (es) * | 2018-02-21 | 2020-12-07 | Five Prime Therapeutics Inc | Regímenes de dosificación de anticuerpo b7-h4. |
| WO2019165116A1 (en) | 2018-02-26 | 2019-08-29 | Fred Hutchinson Cancer Research Center | Compositions and methods for cellular immunotherapy |
| EP3759142A1 (en) | 2018-03-02 | 2021-01-06 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
| WO2019195409A1 (en) * | 2018-04-03 | 2019-10-10 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams |
| KR102480815B1 (ko) | 2018-05-31 | 2022-12-26 | 글라이코넥스 인코포레이티드 | 바이안테나리 루이스 b 및 루이스 y 항원에 결합하는 치료 항체 |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
| MX2021001938A (es) | 2018-08-22 | 2021-04-19 | Fred Hutchinson Cancer Center | Inmunoterapia dirigida a antigenos kras o her2. |
| WO2020068702A1 (en) | 2018-09-24 | 2020-04-02 | Fred Hutchinson Cancer Research Center | Chimeric receptor proteins and uses thereof |
| EP3877404A2 (en) | 2018-11-09 | 2021-09-15 | Fred Hutchinson Cancer Research Center | T cell receptors specific for mesothelin and their use in immunotherapy |
| WO2020132091A2 (en) | 2018-12-19 | 2020-06-25 | Humabs Biomed Sa | Antibodies that neutralize hepatitis b virus and uses thereof |
| WO2020140070A1 (en) * | 2018-12-27 | 2020-07-02 | Gigagen, Inc. | Anti-b7-h4 binding proteins and methods of use thereof |
| CN114026116A (zh) | 2019-02-20 | 2022-02-08 | 弗雷德哈钦森癌症研究中心 | Ras新抗原特异性结合蛋白及其用途 |
| BR112021017703A8 (pt) | 2019-03-11 | 2023-04-18 | Hutchinson Fred Cancer Res | Receptores de células t wt1 de alta avidez e usos dos mesmos |
| KR102716165B1 (ko) * | 2019-03-21 | 2024-10-15 | 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 | 항-b7s1 폴리펩티드 및 이의 용도 |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| US20220409661A1 (en) | 2019-08-20 | 2022-12-29 | Fred Hutchinson Cancer Research Center | T-cell immunotherapy specific for wt-1 |
| WO2021042000A1 (en) | 2019-08-29 | 2021-03-04 | Vir Biotechnology, Inc. | Antibody compositions and methods for treating hepatitis b virus infection |
| EP4076434A1 (en) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| AU2021213840A1 (en) * | 2020-01-31 | 2022-09-29 | Suzhou Zelgen Biopharmaceuticals Co. Ltd. | Bispecific T cell engagers |
| CN116390943A (zh) | 2020-06-24 | 2023-07-04 | 维尔生物科技有限公司 | 工程化乙型肝炎病毒中和抗体和其用途 |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| TWI821699B (zh) * | 2020-06-30 | 2023-11-11 | 大陸商諾納生物（蘇州）有限公司 | 抗b7h4抗體及其雙抗和應用 |
| IL310780A (en) | 2020-08-18 | 2024-04-01 | Abl Bio Inc | Anti-b7-h4/anti-4-1bb bispecific antibodies and use thereof |
| JP2023542528A (ja) | 2020-09-24 | 2023-10-10 | フレッド ハッチンソン キャンサー センター | Ｓｏｘ２抗原を標的とする免疫療法 |
| WO2022066973A1 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting pbk or oip5 antigens |
| TW202222841A (zh) | 2020-10-06 | 2022-06-16 | 福瑞德哈金森腫瘤研究中心 | 用於治療表現mage-a1之疾病的組成物及方法 |
| US20250032540A1 (en) | 2020-12-14 | 2025-01-30 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| AU2022205057A1 (en) | 2021-01-04 | 2023-07-13 | Mersana Therapeutics, Inc. | B7h4-targeted antibody-drug conjugates and methods of use thereof |
| US20240092872A1 (en) | 2021-01-26 | 2024-03-21 | Vir Biotechnology, Inc. | Compositions and methods for treating hepatitis b virus infection |
| KR20230162013A (ko) | 2021-03-26 | 2023-11-28 | 이나뜨 파르마 에스.에이. | Nk 세포 관여를 위해 사이토카인에 융합된 nkp46-결합 부위, 암 항원 결합 부위를 포함하는 다중특이적 단백질 |
| CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| CN117616050A (zh) | 2021-06-09 | 2024-02-27 | 先天制药公司 | 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质 |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| TW202317602A (zh) | 2021-07-15 | 2023-05-01 | 福瑞德哈金森腫瘤中心 | 嵌合多肽 |
| AU2022402985A1 (en) | 2021-12-01 | 2024-07-11 | Kadmon Corporation, Llc | B7-h4 antibodies and anti-b7-h4 antibody/il-15 fusion proteins |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| TW202411246A (zh) | 2022-05-23 | 2024-03-16 | 美商維爾生物科技股份有限公司 | 經工程化之b型肝炎病毒中和抗體及其用途 |
| EP4598946A1 (en) | 2022-10-05 | 2025-08-13 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| CN120435302A (zh) | 2023-01-09 | 2025-08-05 | 普罗塔拉治疗公司 | 化脓性链球菌非活细胞与免疫检查点抑制剂联合治疗三阴性乳腺癌和非肌层浸润性膀胱癌 |
| WO2024208818A1 (en) | 2023-04-04 | 2024-10-10 | Innate Pharma | Modular chimeric antigen receptor |
| WO2025081123A1 (en) | 2023-10-12 | 2025-04-17 | Fred Hutchinson Cancer Center | Methods and compositions for improving t cell immunotherapy |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2025245169A1 (en) | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
| US12551514B1 (en) | 2025-07-25 | 2026-02-17 | Protara Therapeutics, Inc. | Combination of non-viable cells of Streptococcus pyogenes and immune checkpoint inhibitor for the treatment of triple negative breast cancer and non-muscle invasive bladder cancer |
| CN120737193B (zh) * | 2025-09-03 | 2025-12-16 | 中山大学 | 一种抗Oya病毒核衣壳蛋白的单克隆抗体或其抗原结合片段及其应用 |
Family Cites Families (141)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| ATE37983T1 (de) | 1982-04-22 | 1988-11-15 | Ici Plc | Mittel mit verzoegerter freigabe. |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
| GB8808015D0 (en) | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US20040049014A1 (en) | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
| WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| CA2071867A1 (en) | 1989-11-06 | 1991-05-07 | Edith Mathiowitz | Method for producing protein microspheres |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2109528A1 (en) | 1991-05-01 | 1992-11-02 | Gregory A. Prince | A method for treating infectious respiratory diseases |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5120727A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Rapamycin dimers |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US6787153B1 (en) | 1991-06-28 | 2004-09-07 | Mitsubishi Chemical Corporation | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
| US5202332A (en) | 1991-08-07 | 1993-04-13 | American Home Products Corporation | Rapamycin analog as immunosuppressant |
| US5162333A (en) | 1991-09-11 | 1992-11-10 | American Home Products Corporation | Aminodiesters of rapamycin |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| JPH07505628A (ja) | 1992-03-30 | 1995-06-22 | アメリカン・ホーム・プロダクツ・コーポレイション | 静脈注射用のラパマイシン製剤 |
| EP1498427B1 (en) | 1992-08-21 | 2009-12-16 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CH686365A5 (de) | 1992-10-06 | 1996-03-15 | Werner Hofliger | Mobilkran. |
| US5434260A (en) | 1992-10-13 | 1995-07-18 | American Home Products Corporation | Carbamates of rapamycin |
| US5489680A (en) | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
| US5441050A (en) | 1992-12-18 | 1995-08-15 | Neoprobe Corporation | Radiation responsive surgical instrument |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
| US5387680A (en) | 1993-08-10 | 1995-02-07 | American Home Products Corporation | C-22 ring stabilized rapamycin derivatives |
| US5385908A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
| NZ277498A (en) | 1993-12-17 | 1998-03-25 | Novartis Ag | Rapamycin derivatives |
| US5362735A (en) | 1994-02-23 | 1994-11-08 | Smithkline Beecham Corporation | Rapamycin derivatives |
| CA2207961A1 (en) | 1995-01-05 | 1996-07-11 | Robert J. Levy | Surface-modified nanoparticles and method of making and using same |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| AU710347B2 (en) | 1995-08-31 | 1999-09-16 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US5780462A (en) | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
| US5942328A (en) | 1996-02-29 | 1999-08-24 | International Business Machines Corporation | Low dielectric constant amorphous fluorinated carbon and method of preparation |
| DK0885002T3 (da) | 1996-03-04 | 2011-08-22 | Penn State Res Found | Materialer og fremgangsmåder til forøgelse af cellulær internalisering |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| CA2277801C (en) | 1997-01-16 | 2002-10-15 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US5989591A (en) | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
| SI0970126T1 (en) | 1997-04-14 | 2001-08-31 | Micromet Ag | Novel method for the production of antihuman antigen receptors and uses thereof |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| US5843597A (en) | 1997-12-01 | 1998-12-01 | Eveready Battery Company, Inc. | Ribbed gasket for miniature galvanic cell |
| US6982323B1 (en) | 1997-12-23 | 2006-01-03 | Alexion Pharmaceuticals, Inc. | Chimeric proteins for diagnosis and treatment of diabetes |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| CA2336139C (en) | 1998-06-24 | 2008-10-14 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| GB9814640D0 (en) | 1998-07-06 | 1998-09-02 | Fujisawa Pharmaceutical Co | New use |
| US6015809A (en) | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
| US7737255B1 (en) | 1998-09-02 | 2010-06-15 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating various cancers |
| US6311415B1 (en) | 1998-09-14 | 2001-11-06 | Lind Shoe Company | Bowling shoe with replaceable tip |
| US7888477B2 (en) | 1998-12-17 | 2011-02-15 | Corixa Corporation | Ovarian cancer-associated antibodies and kits |
| US6962980B2 (en) | 1999-09-24 | 2005-11-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6891030B2 (en) | 2000-07-27 | 2005-05-10 | Mayo Foundation For Medical Education And Research | T-cell immunoregulatory molecule |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| FR2844455B1 (fr) | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
| FR2844513B1 (fr) | 2002-09-13 | 2007-08-03 | Lab Francais Du Fractionnement | Anticorps pour adcc et induisant la production de cytokines. |
| WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| ATE472338T1 (de) | 2003-02-20 | 2010-07-15 | Seattle Genetics Inc | Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs |
| WO2004084933A1 (en) | 2003-03-28 | 2004-10-07 | Faron Pharmaceuticals Oy | Elevation of adenosine level by cytokine-induced expression of cd73 |
| EP1633784B1 (en) | 2003-05-09 | 2011-07-13 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
| US20050208627A1 (en) | 2003-09-18 | 2005-09-22 | Bowdish Katherine S | Elicitation of antibodies to self peptides in mice by immunization with dendritic cells |
| WO2006007539A1 (en) | 2004-07-01 | 2006-01-19 | Virxsys Corporation | Vector packaging cell line |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US7964195B2 (en) | 2005-01-07 | 2011-06-21 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
| US20090041783A1 (en) * | 2005-04-28 | 2009-02-12 | Mochida Pharmaceutical Co., Ltd. | Anti-platelet membrane glycoprotein vi monoclonal antibody |
| US20090118175A1 (en) | 2005-05-06 | 2009-05-07 | Macina Roberto A | Compositions and Methods for Detection, Prognosis and Treatment of Breast Cancer |
| CN104436190A (zh) | 2005-06-08 | 2015-03-25 | 达纳-法伯癌症研究院公司 | 通过抑制程序性细胞死亡1(pd-1)途经治疗持续性感染和癌症的方法及组合物 |
| CA2612355A1 (en) | 2005-06-16 | 2006-12-28 | Virxsys Corporation | Antibody complexes |
| JP2006345852A (ja) | 2005-06-16 | 2006-12-28 | Virxsys Corp | 抗体複合体 |
| CA2624730A1 (en) | 2005-10-04 | 2007-04-12 | The John Hopkins University | Compositions and methods for treating inflammation |
| KR20080090411A (ko) | 2005-12-08 | 2008-10-08 | 유니버시티 오브 루이빌 리서치 파운데이션, 인코포레이티드 | 면역자극 조성물 및 방법 |
| NZ568015A (en) * | 2005-12-08 | 2012-03-30 | Medarex Inc | Human monoclonal antibodies to O8E |
| US20070160578A1 (en) | 2005-12-14 | 2007-07-12 | The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services | Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes |
| WO2007082154A2 (en) | 2006-01-05 | 2007-07-19 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
| WO2007087341A2 (en) | 2006-01-25 | 2007-08-02 | The Board Of Trustees Of The University Of Illinois | Tolerogenic biodegradable artificial antigen presenting system |
| GEP20135917B (en) | 2006-03-17 | 2013-09-10 | Biogen Idec Inc | Stabilized polypeptide compositions |
| US9121853B2 (en) | 2006-03-20 | 2015-09-01 | Mayo Foundation For Medical Education And Research | B7-H4 expression on tumor vasculature |
| CA2639070A1 (en) | 2006-04-13 | 2007-11-01 | Oncomethylime Sciences S.A. | Novel tumour suppressor |
| WO2007124361A2 (en) | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
| CA2673752A1 (en) | 2006-12-27 | 2008-07-10 | The Johns Hopkins University | Compositions and methods for stimulating an immune response |
| US7989173B2 (en) * | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
| US20090142342A1 (en) | 2006-12-27 | 2009-06-04 | Johns Hopkins University | B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases |
| CA2676143A1 (en) | 2007-01-26 | 2008-07-31 | University Of Louisville Research Foundation, Inc. | Modification of exosomal components for use as a vaccine |
| CA2678180A1 (en) | 2007-02-13 | 2008-12-04 | Northeastern University | Methods and compositions for improving immune responses |
| TW200938224A (en) * | 2007-11-30 | 2009-09-16 | Medarex Inc | Anti-B7H4 monoclonal antibody-drug conjugate and methods of use |
| US20110020325A1 (en) | 2008-02-29 | 2011-01-27 | Kwon Eugene D | Methods for reducing granulomatous inflammation |
| US20100227335A1 (en) | 2009-03-05 | 2010-09-09 | Becton, Dickinson And Company | Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer |
| US8252904B2 (en) | 2009-03-06 | 2012-08-28 | Tripath Imaging, Inc. | Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer |
| US8445207B2 (en) | 2009-04-07 | 2013-05-21 | Korea Institute Of Science And Technology | Genes based on thalidomide, valproic acid and methotrexate treatment for screening of drug inducing teratogenicity and screening method using thereof |
| WO2010144295A1 (en) | 2009-06-09 | 2010-12-16 | University Of Miami | Aptamer-targeted costimulatory ligand aptamer |
| WO2011005566A2 (en) | 2009-06-23 | 2011-01-13 | University Of Miami | Aptamer-targeted sirna to inhibit nonsense mediated decay |
| ES2624835T3 (es) | 2009-08-06 | 2017-07-17 | Immunas Pharma, Inc. | Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos |
| CA2772204A1 (en) | 2009-08-31 | 2011-03-03 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
| JP6072771B2 (ja) * | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| US9676854B2 (en) * | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
-
2013
- 2013-12-19 WO PCT/US2013/076619 patent/WO2014100439A2/en not_active Ceased
- 2013-12-19 WO PCT/US2013/076701 patent/WO2014100483A1/en not_active Ceased
- 2013-12-19 SG SG11201504764SA patent/SG11201504764SA/en unknown
- 2013-12-19 RU RU2015129551A patent/RU2015129551A/ru not_active Application Discontinuation
- 2013-12-19 CN CN201380066946.1A patent/CN104955475A/zh active Pending
- 2013-12-19 EP EP13815940.5A patent/EP2934575A2/en not_active Withdrawn
- 2013-12-19 KR KR1020157017826A patent/KR20150100716A/ko not_active Withdrawn
- 2013-12-19 BR BR112015014063-7A patent/BR112015014063A2/en not_active IP Right Cessation
- 2013-12-19 JP JP2015549737A patent/JP2016509582A/ja active Pending
- 2013-12-19 CA CA2894689A patent/CA2894689A1/en not_active Abandoned
- 2013-12-19 US US14/654,074 patent/US9574000B2/en not_active Expired - Fee Related
- 2013-12-19 AU AU2013361231A patent/AU2013361231A1/en not_active Abandoned
- 2013-12-19 CA CA2894879A patent/CA2894879A1/en not_active Abandoned
- 2013-12-19 EP EP13818155.7A patent/EP2934576A1/en not_active Withdrawn
- 2013-12-19 JP JP2015549721A patent/JP2016505843A/ja active Pending
- 2013-12-19 HK HK15110787.9A patent/HK1210027A1/xx unknown
- 2013-12-19 MX MX2015007846A patent/MX2015007846A/es unknown
- 2013-12-19 AU AU2013361275A patent/AU2013361275B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016509582A5 (enExample) | ||
| Bacac et al. | CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies | |
| RU2015129551A (ru) | Антитела к в7-н4 человека и их применение | |
| KR102349056B1 (ko) | Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법 | |
| US10633450B2 (en) | Methods for enhancing anti-tumor antibody therapy | |
| Lopez-Albaitero et al. | Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody | |
| JP2023129543A (ja) | 抗ｃｄ７３抗体およびそれらの使用方法 | |
| JP2014531409A5 (enExample) | ||
| ES2951650T3 (es) | Uso de un anticuerpo anti-PD-1 junto con un anticuerpo anti-CD30 en el tratamiento del linfoma | |
| RU2018107047A (ru) | Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения | |
| JP7453971B2 (ja) | Ｎｋエンゲージャー分子およびその使用方法 | |
| JP2016520082A5 (enExample) | ||
| JP2020038216A (ja) | 免疫応答を調節するための組成物および方法 | |
| JP2016509585A5 (enExample) | ||
| US20230406918A1 (en) | Method of treatment of a tumor with il-8 antibody | |
| JP2020524149A5 (enExample) | ||
| JP2016538297A5 (enExample) | ||
| CN101678101B (zh) | 可用于诊断和治疗b细胞慢性淋巴细胞白血病的能够在肿瘤细胞中诱导凋亡的药物组合物 | |
| US20250043023A1 (en) | Targeting moiety-drug grafted immune cell compositions and methods of use | |
| US20240374644A1 (en) | Herv-k antibody therapeutics | |
| CA3231445A1 (en) | B7-h3 targeting fusion proteins and methods of use thereof | |
| Ploeg | Novel approaches towards cancer-directed immune checkpoint inhibition | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| Zhang | 286P Nanobody-engineered bispecific IL-18 mimetics bypass IL-18BP and activate CD8+ T cells for potent antitumor immunity | |
| Gross et al. | CD19× CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease |